Alzheimer's & Dementia: Translational Research & Clinical Interventions

Background: Low-dose levetiracetam is under investigation as a potential treatment for slowing Alzheimer's Disease progression. This study tests whether levetiracetam enhances executive function in mid-age adults, and whether drug effects differ by Apolipoprotein e4 (APOE4+) genetic risk status. Methods: Fifty-eight adults (aged 45-65 years; 27 APOE33; 31 APOE4+) participated in a double-blind, placebo-controlled study of low-dose levetiracetam (125mg bidaily for two-weeks). At the end of each treatment phase, participants completed a switch-inhibition task. Results: Mid-age APOE4+ carriers were significantly slower and showed a greater cost of increasing executive demand than APOE33 individuals. Response times were quicker under levetiracetam, with increased benefits reported in APOE33 individuals, at younger ages, and in individuals with reduced levels of plasma-based biomarkers. Levetiracetam selectively benefitted accuracy in APOE33 individuals. Conclusion: Low-dose levetiracetam enhances executive function in midlife, particularly in individuals at lower risk of Alzheimer's Disease based on age, APOE4 genotype, and proxies of neuropathology.

BackgroundGabapentin prescriptions have increased 123% since 2010, reaching 15.5 million Americans annually. Recent studies suggest gabapentin-dementia associations, but whether concomitant medications modify this risk is unknown. Both gabapentin and calcium channel blockers (CCBs) affect neuronal calcium signaling through distinct mechanisms, raising the possibility of pharmacodynamic interaction. MethodsActive comparator new-user cohort study using Rutgers Clinical Research Data Warehouse (2015-2024). Adults [≥]40 years with hypertension initiating gabapentin (n=28,058) or pregabalin (n=5,733) were followed for incident dementia. Inverse probability of treatment weighted (IPTW) Cox models estimated hazard ratios stratified by baseline CCB exposure. Validation analyses tested CCB subtype specificity (dihydropyridine [DHP] vs verapamil), dementia subtypes (F03/G30/F01), frailty stratification (CKD, stroke), lag periods, falsification outcomes, and non-2{delta} anticonvulsant comparisons. ResultsAmong 33,791 patients (502 dementia events; median follow-up 1.22 years), we identified a novel drug-drug interaction: gabapentin was associated with substantially elevated dementia risk among CCB users (HR=2.22, 95% CI 1.42-3.47, p=0.0005) compared to non-users (HR=1.15, 95% CI 0.99-1.33; interaction p=0.004). A time-varying analysis confirmed this finding: among gabapentin users who initiated CCB during follow-up, CCB-exposed person-time showed 65% higher dementia incidence (Rate Ratio=1.65, 95% CI 1.19-2.29). This interaction showed striking CCB subtype specificity: DHP CCBs drove the signal (HR=3.20) while verapamil showed no interaction (insufficient events for analysis). The signal concentrated in F03 unspecified dementia (HR=1.68, p=0.004) with short latency (median 240 days), consistent with drug-induced cognitive impairment rather than neurodegeneration. Pre-index symptom balance analysis showed 6/6 symptom families balanced between groups, arguing against protopathic bias. The interaction was paradoxically weaker in frail patients (CKD ratio=0.25, stroke ratio=0.14), arguing against confounding by illness severity. Lag analyses showed strengthening over time (HR 2.22[->]3.72), falsification outcomes were largely null (4/7), and non-2{delta} anticonvulsants showed no CCB interaction. ConclusionsWe identified a novel drug-drug interaction whereby DHP CCB co-medication amplifies gabapentin-associated dementia risk, confirmed by time-varying analysis (Rate Ratio=1.65). The DHP-specific signal is biologically plausible given independent evidence that DHP CCBs may adversely affect cognition (DREAM consortium), while the absence of interaction with verapamil aligns with its potential neuroprotective properties identified in drug repurposing studies. The F03-specific pattern suggests drug-induced cognitive impairment that may be reversible. These hypothesis-generating findings identify gabapentin-DHP CCB combinations as a target for cognitive safety monitoring and warrant confirmation with concurrent exposure measurement.

ObjectiveTo examine whether menopausal women who initiate systemic menopausal hormone therapy (MHT) around menopause (45-60 years old) have a different risk of developing dementia than those not taking MHT. DesignSystematic review and meta-analysis of randomised controlled trials and longitudinal observational studies. Risk of bias was assessed using ROB-2 and ROBINS I-V2. Data sourcesMEDLINE, Web of Science, EMBASE, and Cochrane Library to 27 March 2026. Eligibility criteria for selecting studiesStudies which measured dementia or cognitive decline in women who initiated systemic MHT between ages 45-60 or within 5 years of menopause, compared with placebo or no MHT. Authors contacted for additional details if needed. Main outcome measuresDementia, Alzheimers disease (AD), cognitive decline. Results10 studies totalling 213,678 participants (189,525 in studies with the primary population). There was no significant increased risk in women with a uterus for all cause dementia (pooled hazard ratio (HR): 1.12; 95% CI 0.91-1.31, N=78,613, I2 = 96.9%), but increased AD risk (HR: 1.14; 95% CI 1.02, 1.29, N=134,865, I2 = 35.6%). Results were similar in sensitivity analyses including women with or without a uterus. Results for cognitive decline were variable. ConclusionsMHT initiated around the age of menopause should not be prescribed for cognition or dementia prevention. It is not protective against dementia and may increase risk slightly. The magnitude of risk was similar in AD and dementia, but the latter with larger confidence intervals. Studies which followed up individuals rather than on health records lost people to follow up. This may account for difference in cognitive decline outcomes between studies, as people with cognitive impairment and dementia are more likely not to attend. MHT prescribing should balance benefits against risks, including evidence of a small increased dementia risk. There are few high-quality studies, so further research would inform recommendations. Systematic review registration Prospero CRD420251010663 What is already known on this topic?O_LIMenopausal hormone therapy (MHT) is effective for alleviating vasomotor symptoms. Contemporary guidelines recommend treatment should be initiated for such symptoms under age 60 and or within 10 years of menopause onset. C_LIO_LIA large randomised trial on the topic found increased risk of dementia in women initiating MHT after the age of 65. C_LIO_LIIt is unknown whether initiating MHT around the age of menopause impacts the risk of dementia or cognitive decline. C_LI What this study addsO_LIThere was no evidence that taking MHT around the time of menopause decreases the risk of dementia or cognitive impairment. C_LIO_LIThey should not be prescribed for these indications. C_LIO_LIWe were able to find more studies which examine this question by contacting authors for additional data. C_LIO_LIInitiating MHT in women with a uterus around the age of menopause increased the risk of Alzheimers disease slightly, by over 10%, and there is a similar but not significant effect in the fewer studies of all cause dementia. Women with or without a uterus show similar results. C_LIO_LIWe found no significant difference shown in cognitive decline, possibly due to loss to follow up. This may be because most studies of cognitive decline follow up C_LI

Objective: Alzheimer's disease (AD) is a leading cause of death and disability, and treatment options for Alzheimer's disease and related dementias (ADRD) remain limited. We applied a data-driven, mechanism-agnostic Medication-Wide Association Study Plus (MWAS+) framework to identify candidate medications associated with ADRD using longitudinal electronic health record data and explainable artificial intelligence (AI). Methods: We used Veterans Health Administration electronic health record data from January 1999 to May 2022. The initial study population comprised 8,424,715 Veterans aged 65 years or older. Cases were defined by ADRD-related diagnosis codes or ADRD-related medication prescriptions, and controls were free of ADRD diagnosis and ADRD-related medication use. After exclusions and matching on sex, race, age at first encounter, and duration of follow-up, the primary analytic cohort included 505,817 matched case-control pairs (1:1; 1,011,634 Veterans). Longitudinal features were extracted from historical data up to 1 year before the index date and aggregated into 1-year intervals. We developed an upgraded Hybrid Value-Aware Transformer (HVAT 2.0) to jointly learn from longitudinal and nonlongitudinal clinical data while incorporating numerical values associated with clinical concepts, including cumulative medication dose. To enhance interpretability, we applied a medication-specific impact score method to estimate model-derived associations between medication exposure and ADRD risk. Findings: The model demonstrated stable performance across data partitions, with area under the receiver operating characteristic curve values of 0.791 in the training set, 0.772 in the validation set, and 0.775 in the testing set. Metolazone and varenicline were identified as the top 2 candidate medications with negative impact scores, suggesting potentially protective associations with new-onset ADRD. The impact score was -0.196 per unit of cumulative dose for metolazone (1800 mg) and -0.134 per unit for varenicline (280 mg). Although individual-level impact scores varied, most exposed patients had negative scores, including 12,020 of 12,480 metolazone users (96%) and 8,341 of 8,786 varenicline users (95%). Implications: This study demonstrates the feasibility of combining a medication-wide association framework, longitudinal dose-aware modeling, and explainable AI to identify candidate medications for ADRD from real-world electronic health record data. The findings should be interpreted as signals for hypothesis generation rather than evidence of causality. This framework may support prioritization of repurposing candidates for expert review, follow-up cohort validation, and future clinical investigation.

BackgroundImpairment of brain waste removal contributes to Alzheimers disease etiology and progression. Although hypertension is a risk factor for dementia, little is known about how it affects measures of clearance in human brain. MethodsCross-sectional (n=159) and longitudinal (n=94) analysis of the relationship between blood pressure (BP) and brain clearance. The estimate of brain clearance was measured using positron emission tomography (PET) as the rate of radiotracer (MK-6240) efflux from the lateral ventricles in the 10-30-minute window after tracer injection. We also examined cerebral blood flow, PET-derived tau deposition in the medial temporal lobe, cognition and plasma biomarkers of neurodegeneration. At baseline we compared participants with (n=88) and without (n=71) hypertension. For longitudinal analyses we defined two groups based on systolic BP trajectories from baseline to follow-up: as long-term controlled (n=76) or uncontrolled BP (n=18). ResultsAt baseline, subjects with hypertension had lower ventricular clearance than normotensive controls (Cohens d=0.53, p=0.001). Over the course of the observation period (median 1.85 years) subjects in the uncontrolled BP group experienced a steeper reduction in clearance rates ({beta}=-5.88) than subjects in the controlled BP group ({beta}=-0.81, interaction p=0.039). ConclusionsOur study suggests that hypertension impairs brain clearance of fluids.

Clinical Dementia Rating (CDR) scores are used to classify the cognitive state of patients and are provided within neuroimaging datasets. This is achieved through a standardized clinical assessment that evaluates participants cognitive and functional abilities in everyday life, after which they are given a score ranging from 0 to 3. Where 0 represents no signs of dementia and three represents severe dementia1. These scores are then used to track the progression of dementia over time2. This study explored if these CDR labels within the OASIS-1 dataset produced consistent volumetric separation across the hippocampus, amygdala, and cortex.

STRUCTURED ABSTRACTO_ST_ABSINTRODUCTIONC_ST_ABSA higher incidence of dementia, including Alzheimer s-like pathology, is observed in aged people living with HIV-1. However, mechanisms linking HIV-1 to Alzheimers disease (AD) pathology remain unclear, due to the lack of animal models that allow for concurrent study. METHODSWe created a novel APP knock-in (KI) AD mouse, NOG/APPKM670,671NL/IL-34 (hNAIL) that permits study of progressive brain HIV-1 replication. The mice harbor human microglia-like cells. Four-month-old CD34+ human cell reconstituted mice infected with the HIV-1ADA strain facilitated studies of HIV-1 replication on AD pathologies. RESULTSHIV-1 replication increased A{beta} levels and reduced synaptic and neuronal integrity. Spatial transcriptomics demonstrated distinct A{beta} and HIV-1 transcriptional patterns, whereas dual diseased combinations amplified AD pathology. Neurons showed highest transcriptional change, with genes linked to neuroinflammation, protein trafficking, and synaptic dysfunction. DISCUSSIONThe hNAIL mice enable interrogation of HIV-AD comorbidities, with a future potential for the development of novel therapeutic interventions.

Purpose: To systematically review population-based studies reporting the prevalence and incidence of neurodegenerative diseases among adults aged 50 and older in Russia Methods: We searched Medline, Scopus, Embase, and eLibrary from inception to January 2025. Cross-sectional and cohort studies were eligible if they reported community-based prevalence or incidence of dementia, cognitive impairment, or Parkinson's disease in adults aged 50 and older in Russia. Healthcare and institutionalised populations were excluded. Risk of bias was assessed using the RoB-PrevMH tool, and dementia prevalence from screening tools was adjusted for test sensitivity and specificity. Prevalence estimates were pooled using random- and fixed-effects meta-analysis, stratified by age group and assessment method. Results: Twenty studies met the inclusion criteria. Dementia prevalence ranged from 0.5% to 81.6%, with the lowest estimates from administrative data and the highest from Mini-Cog screening in adults aged 85 and older. Cognitive dysfunction was reported in 12 studies (prevalence 3.1-81.5%). Nine studies reported Parkinson's disease prevalence (0.017-0.31%), with the highest estimate from the only neurologist-assessed population-based study. Conclusion: Prevalence of dementia and Parkinson's disease in Russia varies widely depending on diagnostic method, age group, and study design. Most studies lacked representative sampling and used non-standardised diagnostic criteria. Population-based longitudinal research using validated tools is urgently needed to support public health planning in Russia.

Objectives: To investigate the association between pulse pressure and dementia incidence, independent of other blood pressure measurements and established risk factors, and to assess whether this association differs across dementia subtypes. Design: Prospective population-based study. Setting: UK Biobank. Participants: Of the 502,211 participants in the UK Biobank, 470,986 completed at least one blood pressure measurement and were included in the analysis. These participants were recruited between March 2006 and July 2010 and were followed for up to four assessments through to February 2024. Main outcome measures: Incidence of dementia, identified through linked health records using ICD-9 and ICD-10 diagnosis codes, self-reported diagnoses or records of dementia-specific medication use. The association between pulse pressure and risk of dementia was investigated using Cox proportional hazard models. Models were adjusted for age, sex, education, hearing problems, lipid levels, depression, traumatic brain injury, physical activity, diabetes, smoking, hypertension, body mass index, alcohol consumption and mean arterial pressure. Dementia subtype-specific associations were examined using competing risk models, with cause-specific Cox analyses included as supplementary sensitivity analyses. Results: During a median follow-up of 13 years, 9,028 persons developed dementia (Alzheimer's disease: 3,011; Vascular dementia: 1,270; Dementia with Lewy bodies: 234; Frontotemporal dementia: 191; Other/Mixed dementia: 4,322). Each 10mm Hg increase in pulse pressure was associated with a 5.4% higher risk of dementia (95% confidence interval on hazard ratio: 1.036 to 1.071), even after adjustment for age, mean arterial pressure and other established dementia risk factors. The effects were disproportionately stronger for Alzheimer's disease and vascular dementia, with no clear evidence for increased risk for dementia with Lewy bodies or frontotemporal dementia. Results were robust across sensitivity analyses including alternative blood pressure metrics, complete-case models, and alternative dementia classifications. Conclusions: Pulse pressure is independently associated with incidence of dementia beyond conventional blood pressure measures.

Background and ObjectivesMultifactorial interventions have been reported to be effective in improving cognitive function; however, their long-term effectiveness in community settings remains to be sufficiently examined. This study aimed to investigate the effects of a socially implemented multifactorial intervention program on dementia onset, long-term care insurance certification, and post-intervention cognitive and physical functions. MethodsThis retrospective observational study collected data from three municipalities. The study population comprised individuals suspected of having mild cognitive decline based on cognitive function screening tests conducted by March 31, 2024, and who had been invited to participate in a dementia prevention class, but had not applied for long-term care insurance at the time of the invitation. Participants were classified into class participation and non-participation groups for analysis. Most participants attended the class only once (intervention duration: 4 or 6 months). ResultsData from 104, 218, and 256 individuals were collected from the three municipalities, respectively. No significant association was found between class participation and suppression of dementia onset or long-term care insurance certification in any of the municipalities. Regarding pre-post comparisons among class participants, significant improvements in cognitive function and some physical functions were observed in all the three municipalities. ConclusionsThe multifactorial interventions implemented in community settings showed no effect on dementia onset or health outcomes. However, class participation was associated with improvements in cognitive function and some physical functions. These findings suggest that implementing programs based on evidence can achieve effects similar to those observed in studies conducted under ideal conditions.

Objectives. Despite the body of literature on genetic risk factors for dementia, little is known on protective genetic factors associated with favourable cognitive ageing in the oldest population. In Europe, Italy has a leading position with a swelling population of centenarians, and the urban area of Genoa in the Liguria region has one of the highest prevalence of centenarians. The COOL study is a not-for-profit, multicentric study involving a cohort of centenarians (aged >99) living in the Genoa area. The ultimate aim is the identification of genomic biomarkers associated with cognition in the oldest old population. Results. Participants underwent a semi-structured interview on personal, disease and family history, and a neuropsychological assessment of the main cognitive domains. As of July 2025, we enrolled 88 centenarians (age range: 99-108, median 100.56) with and without cognitive impairment; 32 subjects were followed up. All participants were of Italian ancestry, 81% were female. The cognitive profile in assessed subjects showed a wide range of cognitive health measures (CDR 0-5; MMSE 3-30, median 24). Whole peripheral blood and DNA samples from 67 participants were stored. Conclusions. We demonstrated that the protocol is feasible, and acceptable by participants and their families. A comprehensive phenotype dataset was established, and DNA samples were stored. Centenarians exhibited a broad spectrum of cognitive profiles, from preserved cognition to severe dementia. These findings will eventually allow to interpret the profiles of genomic variants as associated with variability of cognitive performance in centenarians. The molecular underpinnings of healthy cognitive ageing could inform health policy strategies in the general population.

BackgroundIndividual clinical cognitive assessments (CCA) for Alzheimers disease (AD) provide broad disease stratification but are limited in sensitivity and specificity, requiring integration of multiple CCA for optimal disease staging. Recent work from our lab suggests that neuro-metabolic and vascular dysregulation (MVD) occurs early in AD, prior to clinical symptoms, and may provide higher sensitivity and specificity than CCA alone. In this study, we combined three widely accepted CCA with MVD readouts and developed a multimodal ensemble machine learning approach across the AD spectrum to predict disease stage and grade. MethodsAD subjects (N=372) across the disease spectrum with imaging (PET:18F-FDG, MRI:T1w, T2 FLAIR, ASL) and CCAs (ADAS-Cog, CDR, MoCA) data were analyzed from ADNI. Imaging data were registered to MNI152+, z-scored relative to cognitively normal controls, and processed for MVD. A clinical-set-enrichment analysis (CSEA) was developed to link regional brain changes with CCA scores, map changes to functional categories, project them into a 3D Cartesian space, and model trajectories, thus revealing at-risk and resilient regions. In addition, an ensemble machine-learning approach was utilized for disease stage classification, and a disease grading scheme across the AD spectrum was developed to further stratify within disease stages. FindingsRegional data followed an MVD pattern across AD stages stratified by CSEA scores. Females showed greater stage separation along the CCA axis within each region, indicating faster disease progression. Moreover, progression in at-risk brain regions (e.g., mid- and inf-temporal gyri, amygdala) was associated with longer disease path lengths, whereas progression in resilient brain regions (supramarginal gyrus) was not. Moreover, our classification and grading approach can predict AD stage and grade independent of amyloid-beta and tau with high precision and accuracy. InterpretationA framework was developed to evaluate MVD and CCA variations across the AD spectrum, thereby distinguishing at-risk and resilient brain regions. Distinct disease trajectories were identified, and a new data-driven grading scheme was proposed to highlight the potential for precision medicine and therapeutic evaluation. FundingNIH T32AG071444

SUMMARY Background GLP-1 receptor agonists (GLP-1 RAs) are widely used for treatment of type 2 diabetes and obesity and have demonstrated cardiovascular benefits, but their effect on dementia risk is uncertain. We used a drug-target Mendelian randomisation (MR) framework to estimate the causal effect of GLP-1 receptor (GLP-1R) agonism on dementia risk and brain structure. Methods We used single nucleotide polymorphisms (SNPs) in GLP1R to recapitulate the effect of GLP1-RAs against circulating markers of glucose, glycated haemoglobin and outcomes of type 2 diabetes and obesity, to understand if we can reliably proxy agonism at GLP1R using gene variants. We then considered clinical outcomes, including all-cause dementia, vascular dementia, Alzheimer's disease, and neuroimaging outcomes. Analyses were conducted in UK Biobank and replicated in FinnGen and All of Us and results were combined using meta-analysis. Findings Genetically proxied GLP-1R agonism was associated with a 17% lower risk of vascular dementia, with directional consistency across the two largest cohorts. No consistent association was observed for all-cause dementia. An elevated risk of Alzheimer's disease was observed in UK Biobank but was not replicated in FinnGen or All of Us, and the pooled estimate across cohorts was null. There was no consistent evidence of an effect on neuroimaging outcomes, though higher GLP-1R agonism was associated with greater total brain volume. Interpretation Genetic evidence supports a potential protective effect of GLP-1R agonism on vascular dementia, consistent with the established cardio-metabolic benefits of this drug class. The null pooled finding for Alzheimer's disease suggests that GLP-1R agonism does not meaningfully modify neurodegenerative pathways specific to this disease, though results from ongoing clinical trials are awaited. These findings highlight the importance of distinguishing between dementia subtypes when evaluating the cognitive effects of cardiometabolic therapies.

Background: Estimates from high income countries suggest that approximately 40% of dementia cases may be attributable to modifiable risk factors across the life course. However, most evidence informing these estimates originates from high income settings, and population level estimates from sub Saharan Africa remain limited. We aimed to estimate population attributable fractions (PAFs) for modifiable dementia risk factors in the Democratic Republic of the Congo (DRC). Methods: We conducted a cross sectional analysis of community dwelling adults aged 65 years and older enrolled in the Etude du Vieillissement Cognitif et de Demence en Republique Democratique du Congo (EVCD RDC). Prevalence estimates of dementia and associated exposures were derived from prior epidemiological studies in this population. Odds ratios were estimated using logistic regression, and population attributable fractions were calculated by integrating exposure prevalence with effect size estimates. To account for correlations between exposures, communality weights were applied when estimating combined PAFs across risk factors. Findings: Combined modifiable risk factors were estimated to account for 37.3% (95% CI 14.3 to 55.6) of dementia cases in this sample. Poverty had the largest weighted PAF (18.4%, 95% CI 13.3 to 22.8), followed by low educational attainment (11.3%, 95% CI 7.3 to 15.3) and depression (5.8%, 95% CI 2.8 to 8.6). Additional contributors included traumatic events (5.4%), war exposure (2.1%), diabetes (1.3%), and hypertension (1.1%). A hypothetical 15% proportional reduction in these risk factors was estimated to reduce dementia prevalence by 6.4% (95% CI 2.1 to 10.8), corresponding to approximately 10 700 cases prevented in the DRC by 2025. Interpretation: Modifiable risk factors account for a substantial proportion of dementia burden in the DRC, with structural determinants such as poverty and education contributing the largest fractions. Dementia prevention strategies in low and middle income countries may therefore require broader public health approaches that address socioeconomic and structural determinants alongside conventional clinical risk factors.

INTRODUCTIONHealthful dietary patterns may attenuate dementia risk by preserving cerebrovascular health. Prior work has focused on systemic arterial stiffness, but cerebrovascular measures may be more sensitive to neuroprotective effects of diet. We examined associations between Mediterranean diet adherence, prefrontal cortex (PFC) arterial elasticity, and cognition in older adults. METHODSParticipants were 198 older adults (58% female; mean age 65.6 years) from the Newcastle ACTIVate cohort. Mediterranean Diet (MedDiet) scores were derived from the Australian Eating Survey food frequency questionnaire. Pulse Relaxation Function (PReFx), an index of PFC arterial elasticity, was measured using pulse Diffuse Optical Tomography. Cognition was assessed with CANTAB and a cued task-switching paradigm. RESULTSHigher MedDiet was associated with higher PFC arterial elasticity. MedDiet was not associated with cognition, and PReFx did not mediate diet-cognition associations. DISCUSSIONGreater Mediterranean diet alignment was cross-sectionally associated with PFC arterial elasticity, suggesting a pathway through which diet may influence brain health in ageing.

BACKGROUND: Neuropsychiatric symptoms (NPS) are prevalent and debilitating in Alzheimer's disease (AD). Existing pharmacologic treatments are often ineffective and associated with serious adverse events. Identifying modifiable risk factors (MRFs) is critical for prevention and treatment. METHODS: Capitalizing on data from 14,497 individuals with AD from the National Alzheimer's Coordinating Center (NACC) database, we examined longitudinal associations between modifiable risk factors, APOE genotype and NPI-Q-assessed NPS using Cox proportional hazards models adjusted for demographics. RESULTS: Diabetes, alcohol consumption, smoking, and TBI were associated with an increased risk of specific NPS in AD. APOE{varepsilon}4 carrier status was linked to multiple NPS, showing a dose-response relationship. Education, LDL-C, and corrective lenses were protective; hypertension showed no associations. CONCLUSION: These findings strongly suggest that individual MRFs are associated with specific NPS in line with a complex etiology underlying these symptoms. Early detection and management of vascular, lifestyle and sensory factors could reduce NPS.

INTRODUCTION: Postmenopausal estrogen decline may contribute to Alzheimer's disease (AD) risk, but longitudinal evidence linking circulating estrogens to cerebrospinal fluid (CSF) biomarkers is lacking. METHODS: We analyzed 866 female participants from the European Prevention of AD Longitudinal Cohort Study with baseline serum estradiol and estrone measured by liquid chromatography tandem mass spectrometry and repeated CSF measurements of amyloid-beta (A{beta})42, phosphorylated (p) Tau181, and total (t) Tau. RESULTS: Neither estradiol nor estrone was associated with longitudinal A{beta}42. Higher estradiol was associated with lower baseline tau and slower tau increases over time. Baseline estradiol-tau associations were stronger in apolipoprotein E (APOE) {epsilon}4 carriers, though APOE{epsilon}4 did not modify longitudinal associations. Amyloid positivity did not moderate hormone-tau associations but was associated with steeper tau increases over time. Estrone showed no significant associations. DISCUSSION: These findings suggest a more consistent relationship between estradiol and tau-related rather than amyloid-related pathology.

Background: A recent Lancet Commission estimated that up to 45% of Alzheimers Disease and Related Dementias (ADRD) cases could be prevented by addressing modifiable lifestyle risk factors. Meanwhile, genome wide association studies (GWAS) have shown that common genetic variants also account for substantial ADRD risk. Whether a favorable lifestyle can offset risk in genetically predisposed individuals remains unclear. Methods: We conducted a retrospective cohort study of 105,886 participants from the All of Us Research Program enrolled between 2018 and 2023. Participants were over age 49, assigned male or female at birth, of European ancestry, and without ADRD at baseline. ADRD diagnoses were identified via electronic health records (EHR). Fourteen potentially modifiable risk factors for ADRD were assessed using surveys, EHR records, and wearable data. Genetic risk was quantified as a polygenic risk score (PRS) based on 81 independent GWAS loci and APOE E4 genotype. Results: Overall, 967 incident ADRD events occurred over a median follow-up of 3.7 years. Ten out of 13 modifiable risk factors were significantly associated with ADRD. When grouped into risk factor profiles, intermediate and unfavorable modifiable risk factor scores were associated with substantially higher ADRD risk (HR 3.07, 95% CI 2.47, 3.83; HR 8.01, 95% CI 6.39, 10.05, respectively) compared to a favorable lifestyle; APOE E4 dosage and polygenic risk score were also independently associated with ADRD risk. Among individuals in the highest polygenic risk group, a favorable lifestyle reduced ADRD risk from HR 18.63 (95% CI 10.25, 33.86) to 1.90 (95% CI 0.94, 3.81), whereas APOE E4 homozygotes remained at elevated risk even with a favorable lifestyle (HR 6.52, 95% CI 2.97, 14.33). Conclusions: Our data suggest ADRD risk is driven more by modifiable risk factors and APOE genotype than polygenic risk score. Future genomic informed risk assessments for ADRD should calibrate their findings to accurately identify high risk individuals.

Background: Alzheimers disease (AD) is a multifactorial neurodegenerative disorder in which copper dyshomeostasis, mitochondrial stress, oxidative injury and immune dysregulation may contribute to pathogenesis. Cuproptosis, a copper-triggered regulated cell death pathway, has emerged as a potential mechanistic link to AD, but its therapeutic and biomarker implications remain incompletely defined. Methods: We integrated transcriptomic, machine learning, immune infiltration, QSFR, molecular docking, docking validation and ADME analyses using GEO blood- and brain-based AD cohorts. Differentially expressed genes were intersected with curated cuproptosis-related genes, followed by pathway enrichment, construction and validation of a hybrid ensemble classifier, CIBERSORT-based immune correlation analysis, QSFR-driven target prioritization, ligand docking, consensus docking validation and SwissADME profiling. Results: The transcriptomic analyses revealed reproducible AD associated signatures enriched in neurodegenerative, oxidative stress, mitochondrial and inflammatory pathways. Across multiple machine learning models, FDX1, PDHB, PDHA1, DLAT and DLD consistently emerged as the most important cuproptosis-related genes, with the hybrid ensemble achieving the best diagnostic performance. Immune profiling suggested that these genes are linked to distinct immune infiltration patterns. QSFR and docking prioritized FDX1 as a key target and Clioquinol, PBT2 and Ebselen showed the strongest and most consistent binding behavior. Docking validation confirmed reliable pose reproduction and enrichment over decoys, while ADME analysis supported Clioquinol, PBT2 and Ebselen as the most balanced candidates for further consideration. Conclusion: This integrated workflow identifies a cuproptosis-centered mitochondrial gene module as a robust AD signature and highlights Clioquinol, PBT2 and Ebselen as promising repurposing candidates. The findings provide a prioritized computational framework for future experimental validation of copper-linked therapeutic strategies in AD.

4-Methylumbelliferone (4-MU) inhibits hyaluronic acid (HA) synthesis and is currently approved in Europe for biliary spasm. 4-MU administration reduces perineuronal nets (PNNs), and enzymatic degradation of PNNs in mouse models of Alzheimers disease (AD) attenuates memory impairment. Although 4-MU has therapeutic efficacy in rodent models of fibrosis and cancer, it has not been examined in an Alzheimers model. Here, we evaluated the impact of long-term 4-MU treatment in the APP/PS1 amyloid mouse model. From three months of age, mice were on either a vehicle or 4-MU-supplemented diet for 70 days or 52 weeks. Short and long-term 4-MU treatment decreased the soluble parenchymal A{beta}1-42/A{beta}1-40 ratio. Reductions in insoluble amyloid plaque were observed following 52 weeks of treatment. Extended 4-MU administration also reduced PNN intensity and ameliorated spatial memory deficits in APP/PS1 mice. These findings provide support for targeting brain extracellular matrix (ECM) as a therapeutic strategy for AD.